- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01846689
An Open-label Trial to Determine Increased Red Blood Cell Production in Subjects With Anemia of Chronic Disease
April 30, 2013 updated by: Targeted Medical Pharma
An Open-label Trial of an Erythropoietin Stimulating System to Determine Increased Red Blood Cell Production in Subjects Diagnosed With Anemia of Chronic Disease
The objective of this study is to measure the change in blood values after the administration of an amino acid based erythropoietin stimulating system.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Stephanie Pavlik, CRA
- Phone Number: 310-474-9809
- Email: spavlik@ptlcentral.com
Study Locations
-
-
California
-
Los Angeles, California, United States, 90077
- Targeted Medical Pharma
-
Contact:
- Stephanie Pavlik, CRA
- Phone Number: 310-474-9809
- Email: spavlik@ptlcentral.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- M/F patients 18 years old and over, non-pregnant/lactating
- Hemoglobin < 10 female,<11 male
- Ferritin > upper limit of normal for lab indicative of chronic anemia
- Anemia of chronic disease
- Crt. < 3.0
Exclusion Criteria:
- Currently taking other amino acid formulations.
- Pregnant or unwilling to use adequate birth control for the duration of the study.
- Excessive alcohol or illicit drug use.
- Unwilling or unable to sign informed consent.
- Myocardial infarction within the last 6 months.
- Patients ever having taken or currently taking an erythropoietin medication.
- Iron deficiency (add criteria).
- On dialysis.
- Malignancy other than non-melanoma skin cancer within the last 5 years. If has such malignancy, must have documentation of no recurrence for at least 5 years.
- Liver cirrhosis (add criteria).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ESS
Prescription medical food erythropoietin stimulating system
|
Prescription medical food erythropoietin stimulating system
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Hemoglogin/Hematocrit
Time Frame: 28 Days
|
28 Days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Red blood cell count
Time Frame: 28 Days
|
28 Days
|
Reticulocyte count
Time Frame: 28 days
|
28 days
|
IGF-1
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2013
Primary Completion (ANTICIPATED)
August 1, 2013
Study Completion (ANTICIPATED)
September 1, 2013
Study Registration Dates
First Submitted
April 30, 2013
First Submitted That Met QC Criteria
April 30, 2013
First Posted (ESTIMATE)
May 3, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
May 3, 2013
Last Update Submitted That Met QC Criteria
April 30, 2013
Last Verified
April 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- E130426
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia of Chronic Disease
-
Iuliu Hatieganu University of Medicine and PharmacyUnknownAnemia, Iron Deficiency | Anemia of Chronic DiseaseRomania
-
Helwan UniversityCompletedAnemia of Chronic Kidney Disease | Chronic Renal Failure | Chronic Renal Failure AnemiaEgypt
-
Keryx BiopharmaceuticalsCompletedAnemia of Chronic Kidney DiseaseIsrael
-
FerruMax Pharmaceuticals, Inc.Davita Clinical ResearchTerminatedAnemia of Chronic DiseaseUnited States
-
Rufaida MazahirCompletedAnemia of Chronic Kidney DiseaseIndia
-
Bio Sidus SAUnknownAnemia of Chronic Kidney DiseaseArgentina, Paraguay
-
TME Pharma AGCompletedAnemia of Chronic DiseaseBulgaria, Romania, Austria
-
Medical University of ViennaCompletedAnemia of Chronic Kidney DiseaseAustria
-
Dong-A ST Co., Ltd.UnknownAnemia of Chronic Kidney DiseaseTurkey
Clinical Trials on ESS (medical food/drug)
-
Abbott NutritionCompleted
-
Vincent Martin, MDTargeted Medical PharmaTerminated
-
Abbott NutritionCompletedHip FractureRussian Federation
-
Romanian Society for Enteral and Parenteral NutritionNot yet recruitingTrauma | Gastroparesis | Muscle Loss | Metabolism | Nutritional Deficiency | Protein Malnutrition | Calorie Malnutrition ProteinRomania
-
University of South FloridaRecruiting
-
Faeth TherapeuticsRecruitingMetastatic Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic AdenocarcinomaUnited States
-
Vitaflo International, LtdUniversity College London Hospitals; University Medical Center Groningen; University... and other collaboratorsCompletedGlycogen Storage DiseaseUnited States, United Kingdom, France, Netherlands
-
Faeth TherapeuticsWithdrawnMetastatic Colorectal CancerUnited States
-
Targeted Medical PharmaUnknownDiabetic Neuropathy | Chemotherapy Induced Neuropathy | HIV Neuropathy | Trauma Induced NeuropathyUnited States
-
Northwestern UniversityCompletedIrritable Bowel Syndrome | SIBO | Bacterial Overgrowth SyndromeUnited States